Relief from lupus pain can be seen as a placeholder, not unlike that moment before a great discovery, writes columnist ...

The FDA has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, Genentech said.

Protecting your energy is crucial in life with chronic illness, says columnist Marisa Zeppieri, so be sure to avoid things that drain you.

ADI-001 led to reductions in disease activity for seven lupus patients in a clinical trial, with no serious side effects reported, data show.

What is Gazyva for lupus nephritis? Gazyva (obinutuzumab) is a medication approved in the U.S. for adults with active lupus nephritis who are receiving standard therapies. The treatment is given via ...

Seattle Children’s has been cleared by the U.S. Food and Drug Administration (FDA) to start the nation’s first clinical trial testing CAR T-cell therapy in children with systemic lupus erythematosus, ...

Few couples hearing the term “in sickness and in health” at their wedding have thoughts of chronic illness enter their mind. But the reality is, with almost half of the American population dealing ...

Lupus News Today is a digital platform intended to provide the lupus community with the most recent news and information, as well as first-hand community perspectives from our patient and caregiver ...

Levels of distinct immune cells, including certain monocyte subsets, are altered in systemic lupus erythematosus (SLE) patients, research from China indicates. The new study, “Upregulation of CD16- ...

As months turn into years and years turn into decades of living with systemic lupus erythematosus, we begin to record what helps mitigate or temper symptoms before they turn into a full-blown flare.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to RemeGen‘s RC18 (telitacicept) to treat people with systemic lupus erythematosus (SLE). A therapy candidate is put on ...

The U.S. Food and Drug Administration (FDA) has agreed to allow Kyverna Therapeutics to begin clinical testing of KYV-101, the company’s investigational cell therapy for lupus nephritis, a form of ...